The cytokine and chemokine network in psoriasis

被引:153
作者
Nickoloff, Brian J. [1 ,2 ,3 ]
Xin, Hong [1 ,2 ,3 ]
Nestle, Frank O. [4 ]
Qin, Jian-Zhong [1 ,2 ,3 ]
机构
[1] Loyola Univ, Chicago Med Ctr, Dept Pathol, Maywood, IL 60153 USA
[2] Loyola Univ, Chicago Med Ctr, Skin Dis Res Program, Inst Oncol, Maywood, IL 60153 USA
[3] Loyola Univ, Chicago Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[4] Kings Coll London, Sch Med, Div Genet & Mol Med, London SE1 9RT, England
关键词
D O I
10.1016/j.clindermatol.2007.08.011
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Creation and maintenance of psoriatic plaques require a multicellular conspiracy by which prepsoriatic skin becomes infiltrated by a variety of immunocytes triggering changes in the behavior of epidermal keratinocytes and endothelial cells. These complex cellular events require coordination in space and time to achieve the mature plaque. Key molecular coordinators dictating behavior and movement of cells within plaques include cytokines as well as chemokines. These mediators of inflammation play fundamentally important roles in the pathophysiology of psoriasis. The purpose of this chapter is to provide an updated review of cytokine and chemokine networks in psoriatic skin lesions. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:568 / 573
页数:6
相关论文
共 72 条
[1]   Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells [J].
Abrams, JR ;
Kelley, SL ;
Hayes, E ;
Kikuchi, T ;
Brown, MJ ;
Kang, SW ;
Lebwohl, MG ;
Guzzo, CA ;
Jegasothy, BV ;
Linsley, PS ;
Krueger, JG .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (05) :681-693
[2]   Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ- and interleukin-4-induced activation of human keratinocytes [J].
Albanesi, C ;
Scarponi, CS ;
Cavani, A ;
Federici, M ;
Nasorri, F ;
Girolomoni, G .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (01) :81-87
[3]   Interleukin 10 treatment of psoriasis -: Clinical results of a phase 2 trial [J].
Asadullah, K ;
Döcke, WD ;
Ebeling, M ;
Friedrich, M ;
Belbe, G ;
Audring, H ;
Volk, HD ;
Sterry, W .
ARCHIVES OF DERMATOLOGY, 1999, 135 (02) :187-192
[4]   The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [J].
Austin, LM ;
Ozawa, M ;
Kikuchi, T ;
Walters, IB ;
Krueger, JG .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :752-759
[5]  
BERGERS M, 1990, ACTA DERM-VENEREOL, V70, P57
[6]   Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial [J].
Bhushan, M ;
Bleiker, TO ;
Ballsdon, AE ;
Allen, MH ;
Sopwith, M ;
Robinson, MK ;
Clarke, C ;
Weller, RPJB ;
Graham-Brown, RAC ;
Keefe, M ;
Barker, JNWN ;
Griffiths, CEM .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (05) :824-831
[7]   Getting under the skin: The immunogenetics of psoriasis [J].
Bowcock, AM ;
Krueger, JG .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (09) :699-711
[8]   Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α [J].
Boyman, O ;
Hefti, HP ;
Conrad, C ;
Nickoloff, BJ ;
Suter, M ;
Nestle, FO .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (05) :731-736
[9]   INTRALESIONAL CYCLOSPORINE FOR PSORIASIS - RELATIONSHIP OF DOSE, TISSUE-LEVELS, AND EFFICACY [J].
BURNS, MK ;
ELLIS, CN ;
EISEN, D ;
DUELL, E ;
GRIFFITHS, CEM ;
ANNESELEY, TM ;
HAMILTON, TA ;
BIRNBAUM, JE ;
VOORHEES, JJ .
ARCHIVES OF DERMATOLOGY, 1992, 128 (06) :786-790
[10]   CXCR2 ligands and G-CSF mediate PKCα-induced intraepidermal inflammation [J].
Cataisson, Christophe ;
Pearson, Andrea J. ;
Tsien, Margaret Z. ;
Mascia, Francesca ;
Gao, Ji-Liang ;
Pastore, Saveria ;
Yuspa, Stuart H. .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (10) :2757-2766